Richmond Research Institute is pleased to confirm our participation in The Liver Meeting 2025, hosted by the American Association for the Study of Liver Diseases (AASLD), taking place in Washington, DC, from 7th–11th November.
Representing Richmond at the meeting:
• James Rickard, Chief Scientific Officer
James looks forward to connecting with academic and industry leaders to discuss Richmond’s capabilities in:
• Early-phase hepatology and metabolic liver disease trials
• First-in-human and dose-ranging studies
• Non-invasive biomarkers and digital health integration
• Regulatory strategy and multi-regional trial execution
• Patient-centric approaches in complex liver disease research
Attending AASLD 2025 and looking for a trusted partner in liver disease clinical development? Contact us to arrange a meeting with James: info@richmondpharmacology.com
Richmond Research Institute to present key cardiology research at Heart Failure 2025 in Belgrade, Serbia.
The Pathway study is based on pioneering work during the pandemic between clinicians at Richmond Pharmacology and...
Results of landmark gene editing study for ATTR Amyloidosis presented at the International Liver Congress 2022
We studied the cardiac safety of P218 using advanced QTc assessments and found doses of up to 1000mg do not prolong the QTc suggesting a low risk of drug induced arrhythmia.
12-lead resting ECGs are considered essential in clinical trials, but their limitations have led to increasing use of 12-lead Holter monitor devices.
Dr. Taubel explains to the New Scientist why patient safety is pivotal in phase I trials